Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05624879 · ClinicalTrials.gov registry record · NA

Accelerated Resolution Therapy for Early Maladaptive Grief

A NA study of Grief, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
440
Enrollment target
4
Study locations

NCT05624879 is a NA study of Grief that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 440 participants, below the 588-participant average among 12 other Grief trials with a reported enrollment target (25% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05624879, a NA study of Grief, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
440 participants
Enrollment target
4
Study locations

Study Summary

The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.

Conditions Studied

Interventions

  • BEHAVIORAL Accelerated Resolution Therapy
  • OTHER Information and Support

Study Locations (4)

Florida

  • Suncoast Hospice - Clearwater
  • Mayo Clinic Florida - Jacksonville

Arizona

  • Mayo Clinic Arizona - Phoenix

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2023-11-17
Est. Completion 2028-03-14
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT05624879

The ClinicalTrials.gov registry entry for NCT05624879 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 588-participant average among 12 other Grief trials with a reported enrollment target (25% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Grief appearing as the primary indexed condition, and to 2 interventions - of which Accelerated Resolution Therapy is the first listed.

NCT05624879 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05624879 about?

NCT05624879 is a clinical study titled "Accelerated Resolution Therapy for Early Maladaptive Grief". The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals ...

What is the current status of trial NCT05624879?

This trial is currently recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2023-11-17. Estimated completion is 2028-03-14.

What conditions does trial NCT05624879 study?

This clinical trial studies the following conditions: Grief.

What interventions are being tested in trial NCT05624879?

The interventions under investigation include: Accelerated Resolution Therapy (BEHAVIORAL), Information and Support (OTHER).

Who is sponsoring clinical trial NCT05624879?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05624879 being conducted?

This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Grief

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.